Asian Tech Press (Sep 22) -- China-based firm Walvax Biotechnology Co., Ltd. (Walvax) announced Wednesday that its mRNA COVID-19 vaccine has been approved for Phase III clinical trial in Nepal.

The vaccine is called ARCoV, an mRNA COVID-19 vaccine jointly developed by Suzhou Abogen Biosciences, the PLA Academy of Military Science, and Walvax, and is the first mRNA vaccine approved for clinical trials in China. It has recently received the approval for Phase III clinical trial from the Nepalese drug regulatory authority, signaling that the mRNA vaccine has entered Phase III clinical trials in this South Asian country.

According to the previous announcement, Walvax's mRNA vaccine was approved for Phase III clinical trials in Mexico and Indonesia in August.